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The CpG-island methylator phenotype (CIMPþ) in colorectal cancer (CRC) is characterised by frequent hypermethylation of
promoter regions in tumour suppressor genes. Low level methylation of some CpG islands is also seen in the normal colonic mucosa
and increases with age; however, it is still unclear what other factors regulate this phenomenon. The first aim of our study was to
determine whether the level of promoter methylation is elevated in the normal colonic mucosa of patients with CIMP
þ tumours.
The second aim was to investigate whether common, functional polymorphisms in genes involved in methyl group metabolism are
associated with the level of methylation in this tissue. CpG islands within the ERa, MYOD, P16(INK4A), MLH1, APC, P14(ARF), DAPK
and TIMP3 genes were quantitatively evaluated for methylation in normal colonic mucosa from a large series of CRC patients using
the MethyLight assay. Genotyping was carried out for polymorphisms in the MTHFR, TS, MS, MTHFD1 and DNMT3b genes.
Methylation of ERa and MYOD in normal colonic mucosa increased with age and was higher in female subjects. Methylation of
P16(INK4A), MLH1, TIMP3 and DAPK in normal mucosa occurred at a lower level than ERa and MYOD but also increased with age
and was significantly higher in patients with CIMP
þ tumours. The DNMT3b C46359T polymorphism was associated with significantly
less methylation of MYOD and MLH1 and with trends for lower methylation in each of the other CpG islands examined. Our results
demonstrate that age, gender and genetic factors can influence the methylation level of CpG islands in gene promoter regions of
normal colonic mucosa. Further work is required to determine whether such methylation is associated with the development of
CIMP
þ CRC.
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Changes in DNA methylation patterns are frequently observed in
neoplastic cells (Baylin et al, 1998). Both global hypomethylation
(Feinberg and Vogelstein, 1983) and CpG-island hypermethylation
(Toyota et al, 1999) occur simultaneously in colorectal cancer
(CRC); however, there appears to be no relationship between these
epigenetic alterations (Bariol et al, 2003). Hypermethylation of
CpG islands is associated with transcriptional silencing of tumour
suppressor genes including P16(INK4A) (Merlo et al, 1995) and
MLH1 (Kane et al, 1997). The term CpG-island methylator
phenotype (CIMP
þ) was proposed several years ago to describe
tumours that display frequent and concurrent hypermethylation
of multiple CpG islands (Toyota et al, 1999). CIMP
þ CRCs show
characteristic clinical and pathological features that include origin
in the proximal colon, higher frequency in female subjects and
poorly differentiated, mucinous histology (Toyota et al, 1999;
Hawkins et al, 2002; Van Rijnsoever et al, 2002). Whether these
properties arise because of aberrant DNA hypermethylation or
as a consequence of the microsatellite instability (MSI
þ) phenotype
found in a high proportion of CIMP
þ tumours following
methylation-induced transcriptional silencing of MLH1 has been
highly contentious (Yamashita et al, 2003; Frigola et al, 2005).
However, recent evidence suggests that many of the characteristic
features of CIMP
þ tumours including poor differentiation,
mucinous histology, proximal site and BRAF mutation are found
independently of MSI
þ status (Whitehall et al, 2002; Kambara
et al, 2004; Samowitz et al, 2005a,b). The CIMP
þ/MSI
  tumour
subgroup has worse prognosis (Ward et al, 2003; Samowitz
et al, 2005b), but the overall CIMP
þ phenotype may be more
responsive to 5-fluorouracil-based chemotherapy (Van Rijnsoever
et al, 2003).
The methylation of some CpG islands in the normal colonic
mucosa has been shown to increase with age (Issa et al, 1994;
Ahuja et al, 1998; Nakagawa et al, 2001). This has led to a proposal
by Toyota et al (1999) that methylation of some genes in this tissue
is age-related (Type A genes), whereas for other genes the
methylation is cancer-specific (Type C genes). Examples of Type
A genes include ERa and MYOD and for Type C genes they include
P16(INK4A), MLH1 and TIMP3. This classification could be
misleading, however, in that age-related differences in methylation
levels may be quantitative rather than qualitative. Age-related
methylation and subsequent inactivation of tumour suppressor
genes has been suggested as a predisposing factor for the increased
risk of cancer with age (Issa, 1999).
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specific hypermethylation in normal and neoplastic tissues are
largely unknown. Age clearly has some influence, with dietary
folate intake, alcohol consumption and gender also likely to be
important factors (Choi and Mason, 2002; Kim, 2004). Genetic
factors could also play a role in determining the level of normal
tissue DNA methylation and hence the risk of cancer. Common,
functional polymorphisms have been described for several genes
involved in methyl group metabolism. Most attention has so far
focused on variants of the methylenetetrahydrofolate reductase
(MTHFR), thymidylate synthase (TS), methionine synthase (MS),
DNA methyltransferase (DNMT3b) and methylenetetrahydrofolate
dehydrogenase (MTHFD1) genes (Friso et al, 2002; Paz et al, 2002;
Kawakami et al, 2003; Chen et al, 2004; Sharp and Little, 2004).
We previously reported the wild-type MTHFR 677C allele to
be associated with significantly higher concentrations of two
important intracellular folate intermediates compared to 677T
homozygous variants in CRC (Kawakami et al, 2003). These folate
intermediates were present at almost twice the concentration in
CIMP
þ compared to CIMP
  tumours, suggesting that the MTHFR
C677T polymorphism could also influence the level of DNA
hypermethylation by altering the intracellular methyl donor pool.
Work by other groups has implicated this polymorphism in the
level of global DNA methylation in normal tissues (Stern et al,
2000; Friso et al, 2002; Paz et al, 2002).
In the present study, we used a quantitative assay to evaluate the
methylation level in DNA from normal colonic tissue of eight CpG
islands located within gene promoter regions. We were thus able to
investigate for possible influences of age, gender and methyl
group-related genetic factors on the level of CpG-island methyla-
tion. The finding of strong associations between high levels of
normal colonic tissue methylation and the presence of CIMP
þ
tumours suggests that there may be a causal link.
MATERIALS AND METHODS
Tissue samples
Tissue samples from a consecutive series of 199 CRC patients
undergoing elective surgery at the Colorectal Unit of the Royal
Adelaide Hospital were snap frozen in liquid nitrogen within
20–40min after resection and stored at  701C. Patients had been
fasted for 24h prior to surgery. Samples of normal mucosa were
taken as far away as possible from the tumour site and were
morphologically normal in sections used to evaluate the status of
that margin in routine histology. The normal sample was usually
the distal resection margin for proximal colon cancers or the
proximal resection margin for left colon and rectal cancers.
Microsatellite instability status was determined as previously
described by screening for instability at nine microsatellite loci
that included both mononucleotide (BAT-25, BAT-26, BAT-40)
and dinucleotide (D2S123, D10S197, D17S579, D18S34, D5S346,
D17S250) repeats (Ruszkiewicz et al, 2002). Tumours showing
instability at two or more loci were considered to be MSI
þ.
Tumours showing methylation at two or more of six CpG islands
examined (P16(INK4A), MLH1, APC, TIMP3, P14(ARF), DAPK)
were classified as CIMP
þ (Kawakami et al, 2003). Information on
patient age, gender and tumour characteristics (stage, nodal
involvement, grade, mucinous histology, infiltrating lymphocytes)
were obtained from the pathology report. Ethics approval for this
study was received from the Sir Charles Gairdner Hospital Human
Research Ethics Committee.
Methylation analysis
Aliquots of normal mucosa and tumour tissue were sent on dry ice
to the Kanazawa University School of Medicine for extraction of
DNA and quantitative assessment of CpG-island methylation
within the promoter regions of ERa, MYOD, MLH1 (distal
promoter region), P16(INK4A), TIMP3, P14(ARF), APC and DAPK.
This was carried out using the MethyLight assay and oligonucleo-
tide primer sequences described previously (Eads et al, 2001;
Ishiguro et al, 2003; Kawakami et al, 2003). Briefly, tumour DNA
was converted with sodium bisulphite prior to analysis of
methylation using the fluorescence-based, real-time PCR Methy-
Light assay. The results were analysed to obtain a percentage of
methylated reference (PMR) value as described previously (Eads
et al, 2001). ERa, MYOD, TIMP3 and DAPK were evaluated for
methylation in 188 normal mucosal samples; MLH1, P16(INK4A),
p14(ARF) and APC in 100 samples. These were categorised into no
methylation (PMR¼0), low methylation (PMRpmedian value of
positive readings) and high methylation (PMR4median value of
positive readings).
Genotyping
PCR and PCR-RFLP were used to genotype the 28bp tandem
repeat in the enhancer region of TS and the G/C single-nucleotide
polymorphism (SNP) within the triple repeat allele, respectively
(Kawakami and Watanabe, 2003). The HaeIII-digested PCR
product sizes were estimated using 3% agarose gels. Genotyping
for the MTHFR C677T and A1298C SNPs was carried out using
PCR-F-SSCP as described earlier by our laboratory (Grieu et al,
2004). PCR-RFLP was used to genotype for SNPs in the MTHFD1
(G1958A), MS (A919G) and DNMT3b (C46359T) genes using the
restriction enzymes MspI (Promega, Sydney), HaeIII (Promega)
and AvrII (New England BioLabs, Brisbane), respectively, as
described earlier (Paz et al, 2002; Shen et al, 2002; Chen et al,
2004).
Statistical analysis
Statistical analyses were performed using the SPSS software
package (Chicago, IL, USA). As methylation levels are not
normally distributed, median methylation levels between different
groups were compared using the Mann–Whitney U-test, with PMR
values treated as continuous variables. Associations between age
and methylation were evaluated using linear regression, while
associations between methylation levels (categorised as none, low
or high as described above) and clinical, pathological and
genotypic features were evaluated using w
2 and Fishers’ exact test
as appropriate. All P-values given are two tailed with Po0.05 taken
as statistically significant.
RESULTS
The MethyLight assay (Eads et al, 2001) was used to obtain
quantitative estimates for the level of methylation of CpG islands
within the ERa, MYOD, P16(INK4A), MLH1, APC, P14(ARF),
DAPK and TIMP3 genes in normal colonic mucosa from patients
with CRC. Consistent with previous reports (Toyota et al, 1999;
Rashid and Issa, 2004), ERa and MYOD showed high methylation
levels in this tissue (Table 1). P16(INK4A), MLH1, APC, DAPK and
TIMP3 each showed relatively low methylation levels in normal
colonic tissue (mean PMRo1), while P14(ARF) methylation could
not be detected using the MethyLight assay.
ERa and MYOD methylation in normal colonic tissues increased
significantly with patient age (Po0.001 for each; Figure 1). When
methylation levels were categorised into none, low or high,
patients with high ERa and MLH1 methylation were found to be
significantly older than those with no methylation of these genes
(Figure 2A). Patients with high P16(INK4A) and DAPK methylation
also showed trends for older age. Significantly, more female
subjects showed high levels of ERa methylation relative to the no
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smethylation group (Figure 2B), with MYOD methylation showing
the same trend. Almost half of the patients with high ERa
methylation were female subjects compared to only 21% of those
with no methylation of this gene. No associations were seen
between the methylation level of any gene investigated and
anatomical site of the normal mucosa in the large bowel (results
not shown).
Normal colonic tissue from patients with MSI
þ and CIMP
þ
tumours frequently demonstrated high methylation levels, parti-
cularly for the P16(INK4A), MLH1, TIMP3 and DAPK genes
(Figure 3). High methylation levels of MLH1 were seen in the
normal tissue of more than one-third of patients with MSI
þ
tumours and just over half the patients with CIMP
þ tumours.
Similar trends were also apparent for ERa, MYOD and APC.I n
contrast, the absence of detectable methylation for each of the
genes examined in normal mucosa was observed in o10% of
patients with MSI
þ tumours and in o20% of patients with
CIMP
þ tumours. Of the 44 CIMP
þ tumours in this cohort, 28
(64%) were MSI
  and 16 (36%) were MSI
þ, thus allowing us to
examine the CIMP
þ/MSI
  tumour group separately to the
CIMP
þ/MSI
þ group. Although the sample sizes were small, we
observed higher MLH1 methylation (P¼0.05) but lower ERa
methylation (P¼0.025) in the normal mucosa of patients with
CIMP
þ/MSI
þ tumours compared to those with CIMP
þ/MSI
 
tumours. None of the other genes showed significant differences in
methylation level between the two groups.
We next investigated whether common polymorphisms in the
methyl group metabolism genes MS, MTHFR, MTHFD1, DNMT3b
and TS were associated with the levels of CpG-island methylation
in normal colonic tissue. Only the DNMT3b C46359T variant was
consistently associated with altered methylation levels in normal
colonic mucosa. Methylation levels of MYOD and MLH1 were both
significantly lower in DNMT3b TT homozygous patients compared
to the combined CC/CT group of patients (Mann–Whitney U-test,
P¼0.027 and P¼0.013, respectively), with methylation in each of
Table 1 DNA methylation level in the normal colonic mucosa of CRC
patients
CpG-island (N) Mean PMR (range) Median positive PMR
ERa (188) 13.3 (0–99.1) 12.3
MYOD (188) 2.8 (0–19.3) 2.4
P16(INK4A) (100) 0.14 (0–1.1) 0.2
MLH1 (100) 0.17 (0–0.9) 0.3
APC (100) 0.47 (0–5.3) 0.5
DAPK (188) 0.67 (0–4.5) 0.6
TIMP3 (188) 0.78 (0–9.5) 0.6
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Figure 1 Methylation levels for ERa and MYOD in the normal mucosa of
CRC patients in relation to age at diagnosis. Values were determined by
MethyLight assay and are expressed as the percentage of a methylated
reference (PMR). Older age was associated with significantly increased
methylation of ERa and MYOD (Po0.001).
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Figure 2 Methylation levels in normal colonic tissue were categorised
according to no detectable methylation (PMR¼0; open bars), low
methylation (PMR pmedian of positive values; light bars) and high
methylation (PMR 4median of positive values; dark bars). A high level of
methylation in normal colon tissue was associated with older age (A) and
female gender (B) compared to no detectable methylation. *Po0.1;
**Po0.05; ***Po0.01.
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sthe other genes showing the same trend. For each gene, the highest
percentage of DNMT3b TT homozygous genotype was seen in
patients who had no detectable methylation in their normal
colonic mucosa (Figure 4).
DISCUSSION
Type A methylation sites were originally proposed to describe CpG
islands that are methylated in normal tissue and whose methyla-
tion increases with age, with the best-known examples being ERa
and MYOD (Toyota et al, 1999). In contrast, Type C CpG islands
were proposed as being methylated exclusively in tumour tissue,
with P16(INK4A) and MLH1 suggested as examples. In the present
study, we used a quantitative assay to evaluate DNA methylation
levels in normal colonic tissue from CRC patients who underwent
surgical treatment. As expected, methylation levels for ERa and
MYOD in normal colonic mucosa were higher than the other genes
evaluated (Table 1) and increased with age (Figure 1). However, we
obtained clear evidence that methylation levels for P16(INK4A),
MLH1 and DAPK also increased with age in the normal colonic
mucosa (Figure 2A). Moreover, although the strongest associations
between high methylation levels and female gender were observed
for ERa and MYOD, a similar trend was apparent for all other
genes investigated with the exception of APC (Figure 2B). These
results argue against a simple classification of CpG islands into
Type A or Type C and suggest instead that differences in their
methylation levels in normal colonic tissue are quantitative rather
than qualitative.
The second major finding of this study was that promoter
methylation levels in normal colonic mucosa showed no apparent
associations with site in the large bowel. This was an unexpected
observation because tumour methylation levels for most of the
genes examined here are known to be much higher in cancers
arising in the proximal colon compared to those from the distal
colon or rectum (Toyota et al, 1999; Hawkins et al, 2002; Van
Rijnsoever et al, 2002). We caution, however, that additional
studies involving more precise sampling of normal colonic mucosa
from individuals without cancer are required before concluding
that there are no site-related differences in the CpG-island
methylation levels of this tissue.
The third major finding of the current study was the presence of
relatively high methylation levels in the normal colonic tissues
of patients with MSI
þ and CIMP
þ tumours (Figure 3). This was
particularly apparent for P16(INK4A), MLH1, TIMP3 and DAPK
but was seen for all genes examined. Elevated MLH1 methylation
has previously been reported in the normal gastric epithelia of
patients with stomach cancer compared to noncancer individuals
(Waki et al, 2002). Increased MGMT methylation in the normal
mucosa of patients with colon cancers showing MGMT methyla-
tion was also reported recently (Shen et al, 2005). Together, these
observations suggest that methylation levels in the normal colonic
mucosa could serve as markers of risk for the development of CRC
and in particular for the closely related MSI
þ/CIMP
þ subgroup.
Longitudinal studies performed on individuals at high risk of
developing CIMP
þ CRC will be required to test this hypothesis.
Older age and female gender (Figures 1 and 2) are generally
associated with higher methylation levels for most CpG islands in
normal colonic mucosa. However, it is clear that considerable
interindividual variation occurs in the methylation level for this
tissue, with some young patients showing relatively high values
(Figure 1). Genetic, dietary and environmental factors are there-
fore also likely to be important in determining CpG-island
methylation levels. Dietary information was not available for
this patient series and hence could not be investigated. We did,
however, investigate several common, functional polymorphisms
in genes known to play major roles in methyl group metabolism,
with only the DNMT3b C46359T variant found to be associated
with methylation levels in normal mucosa (Figure 4). Although the
sample size was relatively small, all seven CpG islands investigated
in this study showed less methylation in DNMT3b TT homozygous
individuals compared to those with the CC/CT genotype. DNMT3b
mediates de novo DNA methylation, with the C/T transition
polymorphism postulated to increase in vitro transcriptional
activity by 30% (Shen et al, 2002). The lower methylation level
observed here for DNMT3b TT homozygotes is therefore contrary
to expectations and this gene could influence the level of global
DNA methylation independently of the hypermethylation of CpG
islands in promoter regions. Additional studies performed on large
cohorts of noncancer individuals and incorporating dietary
information are required to confirm the novel association reported
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Figure 3 High methylation levels in normal colon tissue were more
often associated with the presence of MSI
þ (A) and CIMP
þ (B) tumours
compared to cases with no detectable methylation. *Po0.1; **Po0.05;
***Po0.01; ****Po0.001. No detectable methylation (open bars), low
methylation (light bars) and high methylation (dark bars) groups are shown.
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Figure 4 Colorectal cancer patients with no detectable methylation in
normal colon tissue were more often homozygous for the DNMT3b
C46359T variant compared to patients with high levels of methylation.
Although not reaching statistical significance, this trend was seen for all
seven genes investigated. No detectable methylation (open bars), low
methylation (light bars) and high methylation (dark bars) groups are shown.
*Po0.1.
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shere between DNMT3b genotype and CpG-island methylation
levels in normal colonic mucosa.
Although the DNMT3b C46359T variant appears to be associated
with CpG-island methylation levels in the normal colonic mucosa
(Figure 4), we have not determined whether this polymorphism
also confers a risk for the development of CIMP
þ CRC. The
contribution of genetic factors to the development of CIMP
þ is
controversial, with some workers reporting an association between
family history of CRC and CIMP
þ (Frazier et al, 2003; Young et al,
2005), but not others (Ward et al, 2004). Functional polymorphisms
in methyl group metabolism and DNA methylation genes are clearly
interesting candidates for further study and are currently being
investigated in large cohorts of well-defined CIMP
þ tumours.
In conclusion, methylation levels for most CpG islands in
normal colonic mucosa increase with age and are higher in female
subjects. Unlike colorectal tumours, methylation levels in the
normal mucosa do not vary according to anatomical site in the
large bowel. In addition to age and gender, a common genetic
variant in the DNA methyltransferase gene DNMT3b also appears
to influence CpG-island methylation levels in normal colonic
mucosa. The methylation levels of several genes in normal colonic
mucosa were associated with the presence of MSI
þ and CIMP
þ
tumours and could thus serve as molecular-based markers of risk
for the development of this CRC subgroup.
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